Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Company Deals

ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M

Fineline Cube Jan 8, 2026
Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Fineline Cube Jan 8, 2026
Company Deals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

Fineline Cube Jan 8, 2026
Company Deals

Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Fineline Cube Jan 6, 2026
Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Fineline Cube Jan 8, 2026
Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Company Drug

Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial

Fineline Cube Sep 9, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...

Company Policy / Regulatory

MofCOM’s 2021 Pharma Distribution Report Shows Market Recovery

Fineline Cube Sep 9, 2022

The Ministry of Commerce (MofCOM) released its annual statistical review of the pharma distribution industry...

Policy / Regulatory

NHSA Issues Notice on Special Treatment of Oral Implant Medical Service Charges

Fineline Cube Sep 9, 2022

The National Healthcare Security Administration (NHSA) has released a Notice on “Carrying out Special Treatment...

Company Drug

Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Sep 9, 2022

The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody...

Company Deals Digital

Realcan Pharma and AWS Expand Partnership for Digital Transformation

Fineline Cube Sep 9, 2022

China-based Realcan Pharmaceutical Group Co., Ltd (SHE: 002589) and Amazon Web Services (AWS) have agreed...

Company Legal / IP

Salipro Biotech Secures Patent Protection for Membrane Protein Stabilization Tech

Fineline Cube Sep 9, 2022

Sweden-based Salipro Biotech AB announced that its core technology for stabilizing membrane proteins for drug...

Company Drug

Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction

Fineline Cube Sep 8, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in...

Company

China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth

Fineline Cube Sep 8, 2022

A total of 449 pharmaceutical and health-tech companies listed in China have released their H1...

Company Deals

Suzhou InnoBM Pharmaceuticals Raises Series A+ Funding for Tumor Immunotherapy

Fineline Cube Sep 8, 2022

China-based Suzhou InnoBM Pharmaceuticals reportedly raised tens of millions of renminbi in a Series A+...

Company Drug

Laekna Therapeutics Doses First Patient in LAE001/LAE002 Study for Prostate Cancer

Fineline Cube Sep 8, 2022

China-based Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in...

Policy / Regulatory

NHSA Reveals Drugs Passing Initial Review for NRDL Inclusion

Fineline Cube Sep 8, 2022

The National Healthcare Security Administration (NHSA) released a notification listing the drugs that have passed...

Company Drug

Innovent’s Tyvyt Combo Shows PFS Benefit in EGFR-Mutant NSCLC

Fineline Cube Sep 8, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced positive results from the Phase III ORIENT-31 study...

Company Deals

Huadong Medicine Pays EUR 105M for 35% Stake in Heidelberg Pharma

Fineline Cube Sep 8, 2022

China’s Huadong Medicine Co., Ltd (SHE: 000963) announced that it has paid a total of...

Company Deals

CStone Pharmaceuticals Partners with Rigen Biotech on Thyroid Cancer RET Gene Testing

Fineline Cube Sep 8, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has entered into a partnership with Shanghai Rigen Biotech to...

Company Deals

Biocytogen and FineImmune Partner on Innovative Cell Therapy Drug Development

Fineline Cube Sep 8, 2022

China-based Contract Research Organization (CRO) Biocytogen (Beijing) Co., Ltd has entered into a collaboration with...

Company Deals

CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech

Fineline Cube Sep 8, 2022

China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd...

Company Deals

Kelun Pharmaceutical Receives USD 35 Million from Merck Sharp & Dohme Corp.

Fineline Cube Sep 8, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that it has received a USD...

Company Drug

Hainan Yuekang’s YK-029A Biosimilar Set for BTD in EGFR ex20ins NSCLC

Fineline Cube Sep 8, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Hainan Yuekang Biological Medicine Co.,...

Company Drug

Walvax Biotech Enrolls First Subject in Phase III HPV Vaccine Study

Fineline Cube Sep 8, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced the first subject enrollment for a Phase...

Company Drug

Sinocelltech’s Ripertamab Officially Launched in China for DLBCL Treatment

Fineline Cube Sep 8, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab...

Posts pagination

1 … 566 567 568 … 605

Recent updates

  • Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer
  • Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal
  • Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia
  • Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC
  • ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Company Drug

Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia

Company Drug

Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.